Boehringer Ingelheim. (10/31/18). "Press Release: Boehringer Ingelheim Achieves Next Expansion Milestone in Biologics Production in the US". Fremont, CA.

	Region	Fremont, CA
	Country	United States (USA)
	Organisation	Boehringer Ingelheim Fremont Inc.
	Group	Boehringer Ingelheim (Group)
	Product	contract manufacturing (biologicals)
	Product 2	bioreactor
	Person	Baiker, Wolfgang (Adrenomed 202101–202203 CEO + Venture Partner at Wellington Partners before Boehringer Ingelheim LEFT)
	Person 2	Buecheler, Uwe (Boehringer 201901 Head of Biopharmaceutical Business Unit)

> Culmination of a €200 million investment in California

> Worldwide capacity for manufacturing biopharmaceutical medicines now exceeds 290,000 liters

> Global manufacturing network for products in Boehringer Ingelheim’s own research pipeline and for contract manufacturing

[Photo] Ribbon-cutting in Fremont
Expansion inauguration with Gary Chiu, Associate Director, Strategic Projects, Boehringer Ingelheim Fremont, Inc.; Uwe Buecheler, Head of Corporate Division Biopharmaceuticals; Honorable Lily Mei, Mayor of the City of Fremont; Jens Vogel, President, Boehringer Ingelheim Fremont, Inc.; Honorable Bob Wieckowski, California State Senator; Wolfgang Baiker, President and CEO, BI USA Corporation, Markus Wollenberg, Director, API Manufacturing, Boehringer Ingelheim Fremont, Inc.

Last week, employees joined with partners in politics and industry to celebrate the completed expansion of Boehringer Ingelheim’s biopharmaceutical manufacturing facility in Fremont, California. With a two-year investment totaling €200 million, the research-driven pharmaceutical company is creating 300 new jobs and increasing its worldwide bioreactor capacity to 290,000 liters. Boehringer Ingelheim is now well-positioned to manufacture future biopharmaceutical medicines, both from its own research pipeline and as a contract manufacturer for other pharmaceutical and biopharmaceutical companies.

“The completion of our expansion in Fremont marks another milestone in our biopharmaceutical growth strategy,” says Dr. Uwe Bücheler, Head of the Biopharmaceuticals Business Unit. “Our locations in the United States, Germany, Austria, and China are contributing to the development of innovative biopharmaceuticals for patients worldwide.”

In 1987 Boehringer Ingelheim brought Actilyse®, one of the first innovative biological medicinal products for the treatment of stroke and acute myocardial infarction, onto the market with a development partner. Today, biopharmaceuticals make up around 40 percent of the active ingredient candidates from the Boehringer Ingelheim research pipeline. Biotech contract manufacturing experienced double-digit growth in the past year and consolidated its global market leadership. Boehringer Ingelheim has an outstanding experience in manufacturing of 31 biopharmaceutical medicines for different customers worldwide.

About Boehringer Ingelheim BioXcellence™

Boehringer Ingelheim is one of the world’s largest manufacturers of biopharmaceuticals. With over 35 years of experience in this field, the company is an industry pioneer and has produced more than 30 biopharmaceuticals for global markets. Represented by the brand Boehringer Ingelheim BioXcellence™, it offers tailor-made contract development and manufacturing services to the industry, providing the entire production technology chain from DNA to fill and finish through its network in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ secures supply throughout the entire product lifecycle — transferring customer projects at any stage, delivering to almost any scale and thereby making outsourcing easy.

For more information please visit www.bioxcellence.com

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Record changed: 2023-06-05